ArticleMolecular and cellular biochemistry2026
The analgesic effect and mechanism of celastrol in formalin-induced inflammatory pain mouse model.
Article in Molecular and cellular biochemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Celastrol (CEL), a quinonic methyl triterpenoid extracted from the rootstock of the plant Tripterygium wilfordii, which shows therapeutic potential in improving inflammatory diseases, tumor, metabolic diseases and neurodegenerative diseases. However, the role of CEL in acute inflammatory pain is still unclear. In our experiment, the inflammatory pain model induced by formalin was used to explore the mechanism and effect of CEL on pain regulation. The results showed that intraperitoneal injection (i.p.) or intragastric gavage (i.g.) of CEL (0.5 mg/kg and 1.0 mg/kg) obviously reduced the time of licking/biting the right hind paw in the formalin test, without affecting normal motor function or voluntary activity. Moreover, both naloxone (NLX, 1.0 mg/kg, co-injected with CEL) and nor-binaltorphimine (nor-BNI, 10 mg/kg, administrated 24 h prior to CEL) significantly antagonized the antinociceptive effect of CEL, indicating that the κ-opioid receptor was involved in the antinociceptive effect of CEL. In addition, CEL significantly up-regulated the gene expression and protein levels of dynorphin mRNA and Oprk1, while did not influence the expression of Penk, Pomc, Oprm1 and Oprd1. The protein expression levels of p-CaMKII, p-ERK and p-CREB were also significantly decreased in the CEL treated group. Moreover, the immunohistochemistry and immunofluorescence results demonstrated the numbers of positive c-Fos and GFAP in the dorsal horn (L4-6) were obviously reduced. However, all of these protein's expression change induced by CEL were blocked by nor-BNI. Thus, our results indicate that CEL may produce analgesic effect through activating KOR, which subsequently reduce the expression of p-CaMKII/ERK/CREB and inhibit the activation of neural cells in the dorsal horn (L4-6).
Indexed as
Identifiers
42701985What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.